A reversible COMT inhibitor
Related Products
Labeled Version(s)
10010571Entacapone-d10
Metabolite(s)
28046cis-Entacapone
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Entacapone

Item No. 14153

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2E-propenamide
CAS Number
130929-57-6
Synonyms
  • OR-611
Molecular Formula
C14H15N3O5
Formula Weight
305.3
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS(pH7.2) (1:1): 0.5 mg/mlEthanol: 5 mg/ml
λmax
224, 309 nm
SMILES
OC1=C(O)C([N+]([O-])=O)=CC(/C=C(C#N)/C(N(CC)CC)=O)=C1
InChi Code
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChi Key
JRURYQJSLYLRLN-BJMVGYQFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $39

    Add

    25 mg

    $68

    Add

    50 mg

    $106

    Add

    100 mg

    $193

    Add
    Product Description

    Entacapone is a reversible catechol O-methyltransferase (COMT) inhibitor (IC50s = 10, 10, 20, and 160 nM for rat duodenum, brain, erythrocyte, and liver COMT, respectively).1 It is selective for COMT over monoamine oxidase A (MAO-A) and MAO-B and phenolsulphotransferase M (PST-M) and PST-P (IC50s = >50 µM). Entacapone (10 mg/kg), in combination with L-DOPA (Item No. 13248) and carbidopa (Item No. 23783), reduces 3-O-methyldopa (3-OMD) levels in the rat striatum and hypothalamus to 52 and 27%, respectively, of the levels in control animals receiving only L-DOPA and carbidopa.2 In a 6-OHDA rat model of Parkinson's disease, entacapone (10 mg/kg), in combination with L-DOPA and benserazide (Item No. 20298), increases contralateral turning behavior and striatal extracellular dopamine levels.3 Entacapone also inhibits contraction of colon longitudinal muscle explants from a 6-OHDA rat model of Parkinson's disease (EC50 = 200 µM).4 Formulations containing entacapone have been used in the treatment of Parkinson's disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nissinen, E., Lindén, I.B., Schultz, E., et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch. Pharmacol. 346(3), 262-266 (1992).

    2. Männistö, P.T., Tuomainen, P., and Tuominen, R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105(3), 569-574 (1992).

    3. Gerlach, M., van den Buuse, M., Blaha, C., et al. Entacapone increases and prolongs the central effects of L-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch. Pharmacol. 370(5), 388-394 (2004).

    4. Li, L.-S., Liu, C.-Z., Xu, J.-D., et al. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson’s disease. World J. Gastroenterol. 21(12), 3509-3518 (2015).